21.50
Anika Therapeutics Inc stock is traded at $21.50, with a volume of 124.92K.
It is up +1.56% in the last 24 hours and up +38.53% over the past month.
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
See More
Previous Close:
$21.17
Open:
$21.17
24h Volume:
124.92K
Relative Volume:
1.48
Market Cap:
$287.73M
Revenue:
$116.26M
Net Income/Loss:
$-11.08M
P/E Ratio:
-27.16
EPS:
-0.7917
Net Cash Flow:
$1.04M
1W Performance:
+0.37%
1M Performance:
+38.53%
6M Performance:
+110.58%
1Y Performance:
+148.84%
Anika Therapeutics Inc Stock (ANIK) Company Profile
Name
Anika Therapeutics Inc
Sector
Phone
(781) 457-9000
Address
32 WIGGINS AVENUE, BEDFORD, MA
Compare ANIK vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
ANIK
Anika Therapeutics Inc
|
21.50 | 294.83M | 116.26M | -11.08M | 1.04M | -0.7917 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.63 | 55.60B | 29.91B | 1.30B | 3.49B | 0.4056 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.77 | 42.81B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
HLN
Haleon Plc Adr
|
9.70 | 43.16B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
ZTS
Zoetis Inc
|
73.79 | 30.39B | 9.51B | 2.64B | 2.14B | 6.0361 |
|
UTHR
United Therapeutics Corp
|
499.73 | 21.95B | 3.17B | 1.29B | 1.01B | 27.09 |
Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-25 | Initiated | B. Riley Securities | Buy |
| Nov-01-24 | Reiterated | Barrington Research | Outperform |
| Aug-14-23 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Mar-07-23 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-09-22 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Oct-14-22 | Resumed | Stephens | Equal-Weight |
| Mar-09-22 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Mar-09-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Nov-16-21 | Initiated | Stephens | Overweight |
| Jul-16-21 | Initiated | UBS | Neutral |
| Dec-16-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-08-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jan-21-20 | Upgrade | Sidoti | Neutral → Buy |
| Jan-10-20 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Nov-05-19 | Initiated | BWS Financial | Sell |
| Sep-24-19 | Reiterated | Barrington Research | Outperform |
| Sep-23-19 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Jul-25-19 | Upgrade | First Analysis Sec | Neutral → Strong Buy |
| Feb-22-19 | Downgrade | First Analysis Sec | Outperform → Neutral |
| Feb-22-19 | Downgrade | Sidoti | Buy → Neutral |
| Jul-27-18 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jun-20-18 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jun-20-18 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| May-04-18 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Feb-23-18 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jan-24-18 | Upgrade | First Analysis Sec | Equal-Weight → Overweight |
| Oct-27-17 | Reiterated | Barrington Research | Outperform |
| May-09-16 | Upgrade | Singular Research | BUY - Long-Term → Buy |
| Apr-27-16 | Downgrade | Northland Capital | Outperform → Market Perform |
| Feb-26-16 | Reiterated | Barrington Research | Outperform |
View All
Anika Therapeutics Inc Stock (ANIK) Latest News
Anika Therapeutics (ANIK) Is Up 11.10% in One Week: What You Should Know - Yahoo Finance
Anika Therapeutics, Inc. (ANIK) stock price, news, quote and history - sg.finance.yahoo.com
Zacks.com featured highlights include OptimumBank, EuroDry, Enova International, Anika Therapeutics and The GEO - Yahoo Finance
ANIK (NASDAQ: ANIK) holder plans Form 144 sale of 16,864 shares - Stock Titan
Anika (ANIK) is on the Move, Here's Why the Trend Could be Sustainable - Yahoo Finance
Anika Therapeutics (NASDAQ:ANIK) Raised to Strong-Buy at Zacks Research - MarketBeat
Anika Therapeutics (ANIK) Insider Gary Fischetti Buys 2,000 Shar - GuruFocus
Anika Therapeutics Inc (ANIK) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Anika Therapeutics (NASDAQ:ANIK) Director Purchases 1,000 Shares - MarketBeat
Anika Therapeutics (ANIK) director purchases 2,000 common shares in market buys - Stock Titan
Anika Therapeutics Lifts Outlook After Margin Surge - TipRanks
Q1 2025 Anika Therapeutics Inc Earnings Call Transcript - GuruFocus
Anika Therapeutics (ANIK) Stock Fair Value Rises After Q2 Beat And Higher Guidance - Yahoo Finance
Anika Therapeutics Gains 29%, Insider Trades Reap Benefit - Moomoo
Wall Street Zen Upgrades Anika Therapeutics (NASDAQ:ANIK) to Strong-Buy - MarketBeat
Anika Therapeutics expands Integrity implant reach with 3,300 U.S. procedures and international availability - Traders Union
Vanguard Capital Management (ANIK) discloses 4.95% beneficial stake in Anika Therapeutics - Stock Titan
B. Riley Adjusts Anika Therapeutics Price Target to $21 From $18, Maintains Buy Rating - Moomoo
B. Riley Securities Maintains Anika Therapeutics(ANIK.US) With Buy Rating, Raises Target Price to $21 - Moomoo
These 2 Biotech Stocks Hit New 52-Week Highs Today – And CORT Clocked Its Best Day In Nearly 16 Months - Stocktwits
Anika Therapeutics Q2 2026 slides: margins surge, guidance raised By Investing.com - Investing.com Nigeria
Anika Therapeutics Inc (ANIK) Q2 2026 Earnings Call Highlights: - GuruFocus
Is Anika Therapeutics Inc (ANIK) On The Rise After Q2 Earnings B - GuruFocus
Transcript : Anika Therapeutics, Inc., Q2 2026 Earnings Call, Jul 29, 2026 - marketscreener.com
Anika Therapeutics Q2 revenue rises 16% to $32.6 million - Quiver Quantitative
Anika: Q2 Earnings Snapshot - KING5.com
BRIEF-Anika Therapeutics Q2 Revenue USD 32.61 Million - TradingView
Tranche Update on Anika Therapeutics, Inc.'s Equity Buyback Plan announced on May 28, 2024. - marketscreener.com
ANIK|Anika Therapeutics Inc|Price:15.010|Chg%:+0.060 - TradingKey
Anika Therapeutics Inc (ANIK) Balance Sheet - TradingKey
Anika Therapeutics Inc (ANIK) Income Statement - TradingKey
Anika Therapeutics Inc (ANIK) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ANIK|Anika Therapeutics Inc|Price:15.030|Chg%:+0.010 - TradingKey
Anika Therapeutics Inc (ANIK) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Anika Therapeutics Inc (ANIK) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Anika Therapeutics Inc (ANIK) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Anika Therapeutics Inc (ANIK) Cash Flow - TradingKey
Anika Therapeutics Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Anika Therapeutics, Inc. Revenue Breakdown – BX:AKP - TradingView
Anika Therapeutics Inc (ANIK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Anika Therapeutics Q1 2026 Earnings: Strong EPS Beat Driven by Operational EfficienciesFree Cash Flow Trends - dars.gov.et
Anika Therapeutics (ANIK) 2026 CG Musculoskeletal Conference Summary - Quartr
Anika Therapeutics (ANIK) Proxy filing Summary - Quartr
Anika Therapeutics (ANIK) Q4 2025 earnings summary - Quartr
Anika Therapeutics (ANIK) AGM 2026 Summary - Quartr
Anika Therapeutics (ANIK) Expected to Post Earnings on Wednesday - MarketBeat
BlackRock Portfolio Management (NASDAQ: ANIK) discloses 4.1% Anika Therapeutics ownership - Stock Titan
Discipline and Rules-Based Execution in ANIK Response - Stock Traders Daily
Anika Therapeutics Expands Revolving Credit Facility Agreement - The Globe and Mail
Anika to Issue Second Quarter 2026 Financial Results on Wednesday, July 29, 2026 - The Manila Times
Anika Therapeutics to issue Q2FY26 results on July 29 - scanx.trade
Anika Therapeutics Inc Stock (ANIK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):